help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. suppl_1, 8-13, October 2005; doi:10.1634/theoncologist.10-90001-8
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bell, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bell, R.

Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data

Richard Bell

The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia

Key Words. Bisphosphonate • Ibandronate • Intravenous • Oral • Bone metastases

Correspondence: Richard Bell, MBBS, FRACP, FRCPA, FAChPM, MRACMA, The Andrew Love Cancer Centre Cancer Services, Medical Oncology, 70 Swanston Street, Geelong, Victoria 3220, Australia. Telephone: 61-35226-7855; Fax: 61-35226-7290; e-mail: richardb{at}barwonhealth.org.au

Metastatic bone disease affects many cancer patients and has a significant disease burden because of complications such as pathologic fractures and severe pain, which affect patient mobility and quality of life. Bisphosphonates are the current standard of care for treating metastatic bone disease. Available agents have shown varying degrees of efficacy in clinical trials, and treatment potential can be limited by efficacy, tolerance, or toxicity issues. Ibandronate (Bondronat®; F. Hoffman-La Roche Ltd., Basel, Switzerland, http://www.roche.com) is a highly potent, single-nitrogen bisphosphonate that is available in i.v. and oral formulations. In phase III trials in breast cancer patients, both formulations reduced the incidence of skeletal complications associated with metastatic bone disease and had significant and sustained effects on bone pain and patient quality of life. Open-label studies of loading-dose ibandronate administered over consecutive days suggest it also may be useful for relieving severe or opioid-resistant metastatic bone pain. New trials have been designed or are in progress that may extend the clinical indications of ibandronate for patients with metastatic bone disease.




This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Ann. Onc., March 1, 2008; 19(3): 420 - 432.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.-J. Body
Bisphosphonates in Metastatic Bone Disease: Renal Safety Matters
Oncologist, October 1, 2005; 10(suppl_1): 1 - 2.
[Full Text] [PDF]

Home page
 The OncologistHome page
J.-J. Body, T. Pfister, and F. Bauss
Preclinical Perspectives on Bisphosphonate Renal Safety
Oncologist, October 1, 2005; 10(suppl_1): 3 - 7.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2005 by AlphaMed Press.